1-cm cervical dilation and (1) Cesarean delivery, (2) labor duration, and (3) rate of instrumentation. As such, the safe period for epidural analgesia has now been pushed back to 1-cm dilation.
Bigger is not always better though. Every study entails risk. In this case withholding epidurals created the risk of lower satisfaction. The authors state that they designed their study to be able to detect a difference in the rate of Cesarean section of 2.3%. It is arguable whether this is a reasonable difference to target. In this case, the authors anticipated proving the null hypothesis. This trial should have been designed to prove "noninferiority" within a reasonable confidence interval.
The authors measured 29 secondary outcomes. The interpretation of statistically significant secondary outcomes can be complex, particularly when the primary outcome does not demonstrate statistical significance, as in this case. 5, 6 A trial this large may detect relatively small difference in secondary outcomes that are clinically trivial or even spurious. For example, the authors followed up with the patients 6 weeks after delivery on breastfeeding success. Early epidural was strongly associated with less success with breastfeeding (P Ͻ 0.0001). Despite the strength of the statistical association, the difference between the two groups was modest (70% success in the early epidural group compared to 78% success in the late epidural group). The physiologic mechanism for breastfeeding problems caused by the difference between 4.8 and 12.6 h of exposure to epidural ropivacaine and sufentanil is difficult to imagine. It is difficult to interpret multiple secondary endpoints in a randomized clinical trial; despite the very low P value, this finding should be considered a novel hypothesis generated by this study that requires further follow-up as a primary endpoint in a subsequent randomized controlled trial. The authors have undertaken this exercise, and their findings are sure to be important.
There are several additional anomalies among the secondary endpoints. For example, the Visual Analog Scale scores in patients receiving an epidural at 1 cm were similar to those in women receiving opioids until the epidural was placed at 4 cm. This seems surprising; a properly functioning epidural should be almost completely effective at blocking labor pain. Although the Visual Analog Scale scores were similar, maternal satisfaction was significantly higher in the early epidural group (84 vs. 62, P Ͻ 0.01). Perhaps the difference in maternal satisfaction was the result of a true difference in pain that was obscured by intersubject variability, or perhaps the difference was the result of increased likelihood of nausea and vomiting in the late epidural group.
Other groups have found an increased incidence of maternal fever related to epidural analgesia. 7 In the study by Wang et al., earlier epidural placement was not a risk factor for maternal fever. The authors found no difference in maternal temperature between groups or any difference in the incidence of neonatal sepsis work-ups.
Prospective randomized trials of this size are not common in our specialty. The study by Wang et al. illustrates both the strength and potential weaknesses of such studies. The strength is that the primary endpoint can be established with great certainty, permitting as assessment of causality. The disadvantage is that for (very unintuitive) statistical reasons, there is a risk of spurious associations being identified among the secondary endpoints. The conservative view is to accept the primary endpoints as definitive and view any associations seen with the secondary endpoints with caution, particularly if a causative mechanism is not evident.
